Physician profile
Ajay Gupta
NPI 1679542880
$260,565.16
in general payments reported to CMS, 2019-2025
19 companies · $57K in 2025
The $57K reported for 2025 was more than what 98% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $32K · 2021: $12K · 2022: $27K · 2023: $33K · 2024: $36K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Honoraria: $26K · Consulting Fee: $24K · Travel and Lodging: $8,845 · Food and Beverage: $3,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,289.50 |
| Honoraria | $26,031.81 |
| Consulting Fee | $23,921.10 |
| Travel and Lodging | $8,845.32 |
| Food and Beverage | $3,384.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $85,673.99 | 2019-2022 | |
| Ucb, INC. | $48,825.69 | 2022-2025 | Fintepla |
| Jazz Pharmaceuticals INC. | $47,592.69 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $25,132.32 | 2023-2024 | Fycompa |
| Neurelis, INC. | $13,719.97 | 2021-2025 | Valtoco |
| Greenwich Biosciences, INC. | $11,238.11 | 2019-2021 | |
| Otter Pharmaceuticals, LLC | $9,000.00 | 2025 | Sympazan |
| Mallinckrodt Hospital Products INC. | $5,700.00 | 2020 | |
| Nobelpharma America, LLC | $4,934.81 | 2025 | |
| Aquestive Therapeutics, INC. | $2,040.00 | 2020-2021 | |
| Argenx US, INC. | $2,012.50 | 2023 | Vyvgart |
| Pyros Pharmaceuticals, INC. | $1,575.00 | 2023 | |
| Biocodex, INC. | $1,256.73 | 2023 | Diacomit |
| Mallinckrodt Enterprises LLC | $855.00 | 2019 | |
| Biogen, INC. | $797.20 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $125.76 | 2022 | |
| Tg Therapeutics, INC. | $52.45 | 2025 | |
| Emd Serono, INC. | $20.34 | 2023 | Mavenclad |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.